Q-omics provides the consensus-scored PHBP3 profile across patient tissues and cancer cell-line models. PHBP3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PHBP3 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, PHBP3 RNA expression shows 6,524 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LIHC, LUAD, and BRCA as cancer lineages where PHBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHBP3 survival associations across molecular data types. PHBP3 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHBP3 RNA expression–survival associations across cancer types. High PHBP3 expression shows unfavorable associations in LIHC, LUAD, STAD, UVM and ACC, but favorable associations in COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PHBP3 RNA expression.
This table summarizes PHBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PHBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHBP3 shows lower tumor expression in KICH and higher tumor expression in LUAD, COAD, HNSC, LIHC and BLCA. The LUAD box plot shows higher PHBP3 RNA expression in tumor versus normal tissue (log2 FC = +0.160, t-test p < 0.001).
This table shows molecular features associated with PHBP3 in patient tissues and cancer cell lines. In patient samples, PHBP3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
